Delays at the federal Food and Drug Administration and dwindling cash resources will force Cyberkinetics to close its doors for good, The Boston Globe reported.
Rhythmia lands N.I.H. grant to develop “heart map” catheter
Rhythmia Medical Inc. won a $200,000 grant from the National Institutes of Health to help it develop its electronic catheter for use during cardiac ablation procedures, Mass High Tech reported.
The Burlington-based startup plans to use its Small Business Innovation Research grant to develop its electronic catheter, which is designed to map the heart and its electrical activity during catheter ablations, in which surgeons remove the damaged cardiac tissue that causes arrhythmia, or irregular heartbeats.
Pulmatrix raises $3 million in funding
Mass High Tech is reporting that Pulmatrix Inc., a Lexington-based biotechnology startup that’s developing inhaled therapies for respiratory infectious diseases, raised $3.5 million.
The company, which isn’t speaking publicly about the financing and only recently came out of stealth mode, is another Robert Langer company financed by Polaris Ventures of Waltham.
Boston Scientific brass get raises after off year
The board of directors at Boston Scientific Corp. gave themselves a 25 percent pay raise and handed out bonuses to top-level executives — including $16.6 million worth of stock to CEO James Tobin — after a year that saw the company’s stock price drop by nearly a third of its value.
Generation Health to boost its Massachusetts footprint
Generation Health is boosting its Boston-area presence with a benefits management system for genetic tests in the Bay State, the Xconomy website reported.
The company has offices hosted at the Waltham offices of health data analytics firm D2Hawkeye and genetic testing laboratory Correlagen Diagnostics Inc.
Aushon Biosystems buys Thermo Fisher’s SearchLight division
Aushon BioSystems Inc.acquired Thermo Fisher Scientific Inc.‘s SearchLight protein array business for an undisclosed amount.
Aushon said it will continue to sell the acquisition’s products and services under the SearchLight brand under the Aushon BioSystems banner.
Ants versus grasshoppers
Some Boston medical devices firms seem to understand the meaning of saving for a rainy day, according to an Xconomy survey of public healthcare companies, but others are less like the proverbial ant and more like the grasshopper in their lack of thrift.
Of the 44 Boston-area life sciences companies trading on public exchanges the website‘s Luke Timmerman examined at the end of 2008, 19 had more than $100 million saved to withstand the current economic downturn.
Still River Systems lands $33 million investment round
Still River Systems Inc. raised $33 million from investors to speed development of its radiation therapy system.
The Littleton-based startup, which is developing a proton-beam radiotherapy therapy system it calls the Monarch250, plans to use the cash to expedite its development.
Investors ponying up for the latest round include new backer Venrock Associates and existing investors Caxton Health and Life Sciences and CHL Medical Partners.
Ants versus grasshoppers
Some Boston medical devices firms seem to understand the meaning of saving for a rainy day, according to an Xconomy survey of public healthcare companies, but others are less like the proverbial ant and more like the grasshopper in their lack of thrift.
AdvaMed forms VC advisory council
The Advanced Medical Technology Assn. created a venture capital advisory council to help its members raise cash from venture capital firms.
Deerfield deals $60 million to Insulet
Healthcare investor Deerfield Management Co. is ponying up $60 million to back Insulet Corp.
The Bedford-based device maker, which is developing the OmniPod insulin management system, posted a fourth-quarter revenue surge of 172 percent and added 2,200 customers, demonstrating the growth potential of the tubing-free insulin pump.
Under the terms of the agreement, Deerfield will provide Insulet with $27.5 million within fifteen business days of inking the deal, with another $32.5 million available at Insulet’s discretion over the next 20 months. The note comes due in 2012.